Changjiang Huang

Title: Changjiang Huang: Innovator in Pharmaceutical Chemistry

Introduction

Changjiang Huang is a prominent inventor based in Tianjin, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 2 patents, his work focuses on addressing critical medical challenges.

Latest Patents

Changjiang Huang's latest patents include innovative compounds that have the potential to improve patient outcomes. The first patent, titled "Thienopyridine derivatives containing unsaturated aliphatic olefinic bond, preparation method and use thereof," presents a compound designed to combat clopidogrel resistance and reduce severe hemorrhagic side effects associated with certain drugs. This invention not only offers a new therapeutic option but also enhances the stability of existing compounds. The second patent, "Thienopyridine ester derivative containing cyano group, preparation method, use and composition thereof," describes a compound that exhibits antiplatelet aggregation activity. This compound can be utilized in the prevention and treatment of cardiac and cerebral vascular diseases, such as coronary artery syndromes and myocardial infarction.

Career Highlights

Throughout his career, Changjiang Huang has worked with notable organizations, including the Tianjin Institute of Pharmaceutical Research and Tianjin Institute of Pharmaceutical Research Co., Ltd. His experience in these institutions has allowed him to advance his research and contribute to the development of effective pharmaceutical solutions.

Collaborations

Changjiang Huang has collaborated with esteemed colleagues, including Lida Tang and Shijun Zhang. These partnerships have fostered a collaborative environment that enhances innovation and research in the pharmaceutical field.

Conclusion

Changjiang Huang's contributions to pharmaceutical chemistry through his innovative patents demonstrate his commitment to improving healthcare. His work addresses significant medical challenges and has the potential to lead to better therapeutic options for patients.